CN114702581B - 增进抗体功效的通用糖型组合物及方法 - Google Patents

增进抗体功效的通用糖型组合物及方法

Info

Publication number
CN114702581B
CN114702581B CN202210185767.0A CN202210185767A CN114702581B CN 114702581 B CN114702581 B CN 114702581B CN 202210185767 A CN202210185767 A CN 202210185767A CN 114702581 B CN114702581 B CN 114702581B
Authority
CN
China
Prior art keywords
antibody
antibodies
ssea
cells
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210185767.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN114702581A (zh
Inventor
翁启惠
吴宗益
马彻
吴汉忠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhou Meiyin
Original Assignee
Central Research Institute In Taiwan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/723,297 external-priority patent/US10023892B2/en
Priority claimed from US14/798,312 external-priority patent/US10150818B2/en
Application filed by Central Research Institute In Taiwan filed Critical Central Research Institute In Taiwan
Publication of CN114702581A publication Critical patent/CN114702581A/zh
Application granted granted Critical
Publication of CN114702581B publication Critical patent/CN114702581B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN202210185767.0A 2015-01-30 2016-01-30 增进抗体功效的通用糖型组合物及方法 Active CN114702581B (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562110338P 2015-01-30 2015-01-30
US62/110,338 2015-01-30
US14/723,297 2015-05-27
US14/723,297 US10023892B2 (en) 2014-05-27 2015-05-27 Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
US14/798,312 2015-07-13
US14/798,312 US10150818B2 (en) 2014-01-16 2015-07-13 Compositions and methods for treatment and detection of cancers
PCT/US2016/015858 WO2016123593A1 (en) 2015-01-30 2016-01-30 Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
CN201680008450.2A CN107614521B (zh) 2015-01-30 2016-01-30 增进抗体功效的通用糖型组合物及方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680008450.2A Division CN107614521B (zh) 2015-01-30 2016-01-30 增进抗体功效的通用糖型组合物及方法

Publications (2)

Publication Number Publication Date
CN114702581A CN114702581A (zh) 2022-07-05
CN114702581B true CN114702581B (zh) 2025-08-01

Family

ID=56544456

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680008450.2A Active CN107614521B (zh) 2015-01-30 2016-01-30 增进抗体功效的通用糖型组合物及方法
CN202210185767.0A Active CN114702581B (zh) 2015-01-30 2016-01-30 增进抗体功效的通用糖型组合物及方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201680008450.2A Active CN107614521B (zh) 2015-01-30 2016-01-30 增进抗体功效的通用糖型组合物及方法

Country Status (11)

Country Link
EP (1) EP3250590B1 (enExample)
JP (1) JP6942633B2 (enExample)
KR (1) KR102620346B1 (enExample)
CN (2) CN107614521B (enExample)
AU (1) AU2016211176B2 (enExample)
CA (1) CA2973886A1 (enExample)
DK (1) DK3250590T3 (enExample)
ES (1) ES2901173T3 (enExample)
IL (1) IL253497B2 (enExample)
TW (1) TWI717333B (enExample)
WO (2) WO2016123591A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107074945B (zh) * 2014-05-27 2021-08-24 中央研究院 增进抗体功效的通用糖型的组合物及方法
AR105910A1 (es) 2015-09-04 2017-11-22 Obi Pharma Inc Matrices de glicano y método de uso
EP3436482A4 (en) 2016-03-29 2020-03-11 OBI Pharma, Inc. ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
CA3021548A1 (en) 2016-04-22 2017-10-26 Obi Pharma, Inc. Cancer immunotherapy by immune activation or immune modulation via globo series antigens
WO2018022933A1 (en) 2016-07-27 2018-02-01 Obi Pharma, Inc. Immunogenic/therapeutic glycan compositions and uses thereof
KR102528998B1 (ko) 2016-07-29 2023-05-03 오비아이 파머 인코퍼레이티드 인간 항체, 제약 조성물 및 방법
CN107778372B (zh) * 2016-08-22 2019-11-26 中国科学院上海药物研究所 一种寡糖连接子以及利用该寡糖连接子制备的定点连接的抗体-药物偶联物
US11491247B2 (en) 2017-05-02 2022-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
JP2021525756A (ja) * 2018-06-01 2021-09-27 オービーアイ ファーマ，インコーポレイテッド 抗グロボｈ又は抗ｓｓｅａ−４抗体を、抗ネガティブ免疫チェックポイント抗体と共に使用することによる組合せ療法
WO2020006176A1 (en) 2018-06-27 2020-01-02 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
CN109620970A (zh) * 2018-11-13 2019-04-16 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种胸腔镜下内乳区前哨淋巴结纳米碳示踪活检及内乳淋巴结清扫方法
WO2021026264A1 (en) 2019-08-05 2021-02-11 Cho Pharma, Inc. Fusion protein for remodeling antibody glycoform
KR20230104192A (ko) 2020-11-06 2023-07-07 초 파마 인크. 항원 및 이의 당쇄조작된 항체를 포함하는 면역 조성물
JP2023553313A (ja) * 2020-11-30 2023-12-21 チョ ファーマ インコーポレイテッド 細胞を富化するための抗体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106661129A (zh) * 2014-08-19 2017-05-10 美天旎生物技术有限公司 对ssea4抗原具有特异性的嵌合抗原受体

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US351A (en) 1837-08-15 James wilson
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU641673B2 (en) 1989-06-29 1993-09-30 Medarex, Inc. Bispecific reagents for aids therapy
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU8295491A (en) 1990-06-29 1992-01-23 Biosource Technologies Incorporated Melanin production by transformed microorganisms
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992019971A1 (en) 1991-04-30 1992-11-12 Alkermes, Inc. Cationized antibodies against intracellular proteins
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
JPH08500962A (ja) 1992-02-06 1996-02-06 クリエイティブ バイオモレキュルズ，インコーポレイテッド 癌マーカー用生物合成結合蛋白質
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DE69334095T2 (de) 1992-07-17 2007-04-12 Dana-Farber Cancer Institute, Boston Verfahren zur intrazellulären Bindung von zielgerichteten Molekülen
AU677216B2 (en) 1992-07-27 1997-04-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Targeting of liposomes to the blood-brain barrier
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US6027888A (en) 1996-04-05 2000-02-22 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
US7863020B2 (en) * 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
WO2002017930A2 (en) 2000-08-30 2002-03-07 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
AU2002338446A1 (en) 2001-01-23 2002-11-05 University Of Rochester Medical Center Methods of producing or identifying intrabodies in eukaryotic cells
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
WO2003009815A2 (en) 2001-07-25 2003-02-06 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
AU2003219277A1 (en) 2002-03-14 2003-09-29 Medical Research Council Intracellular antibodies
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
KR101111477B1 (ko) 2002-12-03 2012-02-23 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 치료제와 연결된 콜레스테롤을 포함하는 접합체
WO2004063351A2 (en) * 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
EP1663239A4 (en) 2003-09-10 2008-07-23 Cedars Sinai Medical Center KALIUM CHANNEL-MEDIATED FEEDING OF MEDICINES BY THE BLOOD BRAIN BARRIER
EP2104513B1 (en) * 2006-11-27 2015-05-20 diaDexus, Inc. Ovr110 antibody compositions and methods of use
MX2009007139A (es) * 2006-12-28 2009-10-08 Centocor Ortho Biotech Inc Metodos y vectores para generar inmunoglobulinas no sialiladas.
AU2008206887B9 (en) * 2007-01-18 2011-07-07 Glykos Finland Oy Novel specific cell binders
CA2685015A1 (en) * 2007-04-23 2008-11-06 Schering Corporation Anti-mdl-1 antibodies
WO2010008736A2 (en) 2008-06-16 2010-01-21 Academia Sinica Cancer diagnosis based on levels of antibodies against globo h and its fragments
JP2011524375A (ja) 2008-06-16 2011-09-01 アカデミア シニカ ＧｌｏｂｏＨおよびＳＳＥＡ３に特異的な免疫反応を誘起する組成物および癌治療におけるその使用
JP2010014691A (ja) * 2008-06-20 2010-01-21 Igaku Seibutsugaku Kenkyusho:Kk 腹水中のメソテリン及び／又は巨核球増強因子を検出するための方法、キット、試薬及び装置
KR101677279B1 (ko) * 2009-06-16 2016-11-29 아카데미아 시니카 신규한 당지질 애주번트를 갖는 ｇｌｏｂｏ ｈ 및 관련 항암 백신
US10087236B2 (en) * 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011074621A1 (ja) * 2009-12-18 2011-06-23 株式会社医学生物学研究所 メソセリン（msln）に対する抗体及びその用途
BR112012020101A2 (pt) * 2010-02-11 2018-09-25 Alexion Pharma Inc método diagnósticos e terapêuticos usando anticorpos anti-cd200.
GB201015569D0 (en) * 2010-09-16 2010-10-27 Medical Res Council Blood assay for prions
WO2012162277A1 (en) * 2011-05-25 2012-11-29 Merck Sharp & Dohme Corp. METHOD FOR PREPARING Fc-CONTAINING POLYPEPTIDES HAVING IMPROVED PROPERTIES
CA2862925C (en) * 2012-02-10 2020-01-21 University Of Maryland, Baltimore Chemoenzymatic glycoengineering of antibodies and fc fragments thereof
WO2013151649A1 (en) * 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
TWI510627B (zh) 2012-08-20 2015-12-01 中央研究院 寡醣之大規模酵素合成
WO2014078373A1 (en) * 2012-11-13 2014-05-22 Iogenetics, Llc Antimicrobial compositions
KR20160104727A (ko) * 2014-01-16 2016-09-05 아카데미아 시니카 암의 치료 및 검출을 위한 조성물 및 방법
WO2016114819A1 (en) * 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
US10118969B2 (en) * 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
CN107074945B (zh) * 2014-05-27 2021-08-24 中央研究院 增进抗体功效的通用糖型的组合物及方法
US9975965B2 (en) * 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106661129A (zh) * 2014-08-19 2017-05-10 美天旎生物技术有限公司 对ssea4抗原具有特异性的嵌合抗原受体

Also Published As

Publication number Publication date
CN107614521B (zh) 2022-02-08
ES2901173T3 (es) 2022-03-21
AU2016211176B2 (en) 2021-01-28
EP3250590A1 (en) 2017-12-06
WO2016123593A1 (en) 2016-08-04
CN107614521A (zh) 2018-01-19
JP6942633B2 (ja) 2021-09-29
CN114702581A (zh) 2022-07-05
JP2018509390A (ja) 2018-04-05
EP3250590B1 (en) 2021-09-15
IL253497A0 (en) 2017-09-28
TWI717333B (zh) 2021-02-01
KR20170108146A (ko) 2017-09-26
WO2016123591A3 (en) 2016-12-15
EP3250590A4 (en) 2018-10-31
CA2973886A1 (en) 2016-08-04
AU2016211176A1 (en) 2017-08-10
KR102620346B1 (ko) 2024-01-02
WO2016123593A9 (en) 2017-12-28
DK3250590T3 (da) 2021-10-18
IL253497B2 (en) 2023-06-01
TW201702268A (zh) 2017-01-16
WO2016123591A2 (en) 2016-08-04

Similar Documents

Publication Publication Date Title
CN114702581B (zh) 增进抗体功效的通用糖型组合物及方法
US10118969B2 (en) Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
CN107406495B (zh) 治疗及检测癌症的组合物及方法
US9982041B2 (en) Compositions and methods for treatment and detection of cancers
US10150818B2 (en) Compositions and methods for treatment and detection of cancers
US9975965B2 (en) Compositions and methods for treatment and detection of cancers
US10980894B2 (en) Antibodies, pharmaceutical compositions and methods
AU2017239637A1 (en) Antibodies, pharmaceutical compositions and methods
WO2016114819A1 (en) Compositions and methods for treatment and detection of cancers
HK40069987A (en) Compositions and methods relating to universal glycoforms for enhanced antibody efficacy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40069987

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20250728

Address after: Georgia, USA

Patentee after: Zhou Meiyin

Country or region after: U.S.A.

Address before: No 128 Section 2 Research Institute Road Nangang District Taipei City Taiwan China

Patentee before: Central Research Institute in Taiwan

Country or region before: Taiwan, China